Judith Anne W Chapman

Summary

Affiliation: Queen's University
Country: Canada

Publications

  1. ncbi Innovative estimation of survival using log-normal survival modelling on ACCENT database
    J W Chapman
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Br J Cancer 108:784-90. 2013
  2. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
  3. ncbi Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada
    BMC Cancer 7:174. 2007
  4. ncbi Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
  5. ncbi Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast
    Naomi A Miller
    Department of Pathology, University Health Network, 200 Elizabeth St, Eaton 11 444, Toronto, Ontario, Canada M5G 2C4
    Cancer Inform 9:209-16. 2010
  6. ncbi Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Patricia Tai
    University of Saskatchewan, Faculty of Medicine, Saskatoon, Saskatchewan, Canada
    BMC Cancer 7:31. 2007
  7. ncbi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
  8. ncbi Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
  9. ncbi Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008

Detail Information

Publications9

  1. ncbi Innovative estimation of survival using log-normal survival modelling on ACCENT database
    J W Chapman
    NCIC Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario, Canada
    Br J Cancer 108:784-90. 2013
    ..We hypothesised substantive differences in survival estimation with log-normal modelling rather than standard Kaplan-Meier or Cox approaches...
  2. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
    ..Estimated prognoses may differ substantially by survival analysis model type, by amounts that might affect patient management, and we think that the log-normal model has a major advantage over the Cox model for survival analysis...
  3. ncbi Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada
    BMC Cancer 7:174. 2007
    ..Here, we used image analysis in addition to histologic evaluation to determine if quantification of nuclear features could provide additional prognostic information and hence impact prognostic assessments...
  4. ncbi Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
    ..We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy...
  5. ncbi Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast
    Naomi A Miller
    Department of Pathology, University Health Network, 200 Elizabeth St, Eaton 11 444, Toronto, Ontario, Canada M5G 2C4
    Cancer Inform 9:209-16. 2010
    ..05). Also, we compared image features for nuclei in patients with single grade to those with the same grade in patients with multiple grades using t-tests...
  6. ncbi Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Patricia Tai
    University of Saskatchewan, Faculty of Medicine, Saskatoon, Saskatchewan, Canada
    BMC Cancer 7:31. 2007
    ..There might be substantive differences from the results using these models for the same patients, if different statistical methods were used, for example, Boag log-normal (cure-rate model), or log-normal survival analysis...
  7. ncbi Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    Kathleen I Pritchard
    Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:3869-76. 2011
    ..This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence...
  8. ncbi Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  9. ncbi Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008
    ....